{"entity":{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","aka":[],"tldr":"The IMDC score uses six factors to sort metastatic kidney cancer into three risk groups. It decides whether dual immunotherapy or immunotherapy plus a targeted pill is offered first.","summary":"International Metastatic RCC Database Consortium (Heng) criteria: Karnofsky <80%, <1 year from diagnosis to treatment, anaemia, hypercalcaemia, neutrophilia, thrombocytosis. 0 factors favourable, 1-2 intermediate, ≥3 poor. Nivolumab-ipilimumab's OS benefit is confined to intermediate/poor risk; IO-TKI doublets benefit all groups on PFS, with less clear OS benefit in favourable risk.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Renal_cell_carcinoma","links":[{"label":"IMDC (Heng) prognostic model for metastatic RCC (Heng et al., J Clin Oncol 2009)","url":"https://doi.org/10.1200/JCO.2008.21.4809"}],"tags":[],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-214","keynote-426","clear"],"people":[],"bottlenecks":[],"keyPapers":["paper-heng-j-clin-oncol"],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/imdc-risk/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"trial":[{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/"},{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/"},{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/"}],"paper":[{"id":"paper-heng-j-clin-oncol","kind":"paper","name":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","route":"/key-papers/paper-heng-j-clin-oncol/"}],"pairing":[{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/"}]}}